跳至主要内容
临床试验/NCT00237016
NCT00237016已完成2 期

Post Exposure Treatment With Doxycycline for the Prevention of Relapsing Fever

Medical Corps, Israel Defense Force2 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2002年4月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
140
试验地点
2

研究概览

简要总结

Abstract Background Tick-Borne Relapsing Fever (TBRF) is an acute febrile illness. In Israel, TBRF is caused by Borrelia persica and is transmitted by Ornithodoros tholozani ticks. We examined the safety and efficacy of a post exposure treatment policy to prevent TBRF.

Methods In a double blind, placebo controlled trial 93 healthy volunteers with suspected tick exposure (51 with bite signs and 42 contacts) were randomly assigned to receive either Doxycycline (200 mg for the first day and 100mg/d for 4 days) or placebo, approximately 2 days after contact. Blood smears were examined for Borrelia at inclusion and during fever rise. Serology for Lyme disease cross- reactivity and PCR for Borrelia GlpQ gene were also performed. Cases of TBRF were defined as subjects having fever and a positive blood smear.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
Double

入排标准

性别
All
接受健康志愿者

入选标准

  • suspected exposure to tick-borne relapsing fever
  • after returning from field exercise in a tick-borne relapsing fever infected area
  • having a tick bite or staying in field in close proximity to a subject with tick bite sign

排除标准

  • known sensitivity to tetracycline or doxycycline
  • febrile illness on recruitment

研究者

发起方
Medical Corps, Israel Defense Force
申办方类型
Other

研究点 (2)

Loading locations...

相似试验